Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Science (New York, N.Y.) | Dec 11, 1998

http://www.ncbi.nlm.nih.gov/pubmed/9851930

Mutations of the gene Lps selectively impede lipopolysaccharide (LPS) signal transduction in C3H/HeJ and C57BL/10ScCr mice, rendering them resistant to endotoxin yet highly susceptible to Gram-negative infection. The codominant Lpsd allele of C3H/HeJ mice was shown to correspond to a missense mutation in the third exon of the Toll-like receptor-4 gene (Tlr4), predicted to replace proline with histidine at position 712 of the polypeptide chain. C57BL/10ScCr mice are homozygous for a null mutation of Tlr4. Thus, the mammalian Tlr4 protein has been adapted primarily to subserve the recognition of LPS and presumably transduces the LPS signal across the plasma membrane. Destructive mutations of Tlr4 predispose to the development of Gram-negative sepsis, leaving most aspects of immune function intact.

Pubmed ID: 9851930 RIS Download

Mesh terms: Amino Acid Sequence | Animals | Chromosome Mapping | Cloning, Molecular | Drosophila Proteins | Genes, Dominant | Gram-Negative Bacterial Infections | Homozygote | Lipopolysaccharides | Macrophages | Membrane Glycoproteins | Mice | Mice, Inbred C3H | Mice, Inbred C57BL | Molecular Sequence Data | Mutation, Missense | Point Mutation | RNA, Messenger | Receptors, Cell Surface | Signal Transduction | Toll-Like Receptor 4 | Toll-Like Receptors

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.